Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...

The use of diabetes and weight-loss medications like Ozempic or Wegovy—called GLP-1 drugs—has exploded in recent years, with ...

Mohammad Ali Sheffeh, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

GLP-1RA medications in preadolescents and adolescents were concentrated among those with diabetes, obesity, mood disorders, and anxiety.

A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying ...

New research, led by experts at the University of Nottingham, has found that certain types of medication used to treat ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

It’s hard to remember a time before Ozempic, Wegovy, and other injectable drugs referred to as GLP-1 receptor agonists (that ...